Skip to main content
Deutsch

Available examinations

  1. Department of Biomedical Imaging and Image-guided Therapy
  2. Our Divisions
  3. Division of Nuclear Medicine
  4. Patient information
  5. Nuclear medicine examinations
  6. Neuronuclear medicine
  7. Available examinations

These examinations are performed to more accurately distinguish neurodegenerative Parkinson's diseases.

 

123I-FP-CIT SPECT (DATSCANTM)
This examination allows for the visualization of presynaptic dopamine transporters, providing insights into potential degeneration of dopaminergic nigrostriatal pathways. Presynaptic dopamine transporters can be detected through neuronuclear medicine in the basal ganglia of the brain.

Indications

  • Detection of a neurodegenerative Parkinson's disease such as Parkinson's disease, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).
  • Assessment of the severity of Parkinson's disease.
  • Evaluation of suspected Lewy body dementia (LBD).

Radiopharmaceutical/Application
150 MBq 123I-FP-CIT administered intravenously in adults. For children, the dosage is adjusted according to weight and age.

 

123I-IBZM SPECT
This examination allows for the visualization of postsynaptic dopamine 2 (D2) receptors, providing insights into potential receptor degeneration or receptor blockade due to medications.

Indications

  • More precise differentiation of neurodegenerative multisystem disorders (MSA, PSP, CBD) from idiopathic Parkinson's disease.
  • Schizophrenia in neuroleptic therapy (60–80% receptor occupancy is beneficial for treatment).

Radiopharmaceutical/Application
180 MBq administered intravenously in adults. For children, the dosage is adjusted according to weight and age.